Schizophrenia Research

• 

  Publication Venue For

  • Associations between cannabis use and retinal vessel diameter in young adults. 2019
  • A Phase II study of a histamine H<inf>3</inf> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.  164:136-142. 2015
  • A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia..  153:246-247. 2014
  • A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia.  153:246-247. 2014
  • Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies.  159:205-210. 2014
  • Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.  159:182-187. 2014
  • The continuous performance test, identical pairs: Norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.  156:233-240. 2014
  • Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis.  151:148-153. 2013
  • The Longitudinal Youth at Risk Study (LYRIKS) - An Asian UHR perspective.  151:279-283. 2013
  • Unraveling the relationship between obesity, schizophrenia and cognition.  151:107-112. 2013
  • The global cognitive impairment in schizophrenia: Consistent over decades and around the world.  150:42-50. 2013
  • Drug and alcohol trajectories among adults with schizophrenia: Data from the CATIE study.  148:126-129. 2013
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial.  146:190-195. 2013
  • Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.  146:217-223. 2013
  • Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.  150:328-333. 2013
  • Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.  150:542-546. 2013
  • Linkage analysis of schizophrenia in African-American families..  109:70-79. 2009
  • CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al..  107:327-329. 2009
  • Commentary on O'Halloran et al.  107:327-329. 2009
  • Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function..  107:275-285. 2009
  • Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial..  107:22-29. 2009
  • Results of phase 3 of the CATIE schizophrenia trial..  107:1-12. 2009
  • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study..  105:175-187. 2008
  • Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study..  105:1-9. 2008
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1..  103:104-109. 2008
  • Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)..  102:108-115. 2008
  • Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1..  101:273-286. 2008
  • Neural bases of different cognitive strategies for facial affect processing in schizophrenia..  100:191-205. 2008
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study..  100:39-52. 2008
  • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study 2008
  • A pilot study of a weight management program with food provision in schizophrenia..  96:198-205. 2007
  • Effectiveness of atypical antipsychotics for substance use in schizophrenia patients..  94:114-118. 2007
  • Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs..  94:45-49. 2007
  • Reduction of synapsin III in the prefrontal cortex of individuals with schizophrenia..  94:366-370. 2007
  • Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia..  91:210-216. 2007
  • Erratum to "Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Recruitment and assessment methods" [Schizophrenia Research 87 (1-3) (2006) 32-44] (DOI:10.1016/j.schres.2006.06.027).  90:369. 2007
  • A longitudinal study of neurocognitive function in individuals at-risk for psychosis..  88:26-35. 2006
  • Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods..  87:32-44. 2006
  • Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline..  86:15-22. 2006
  • Olanzapine and haloperidol in first episode psychosis: two-year data..  86:234-243. 2006
  • Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring..  85:106-112. 2006
  • Comorbid posttraumatic stress disorder is associated with suicidality in male veterans with schizophrenia or schizoaffective disorder..  84:165-169. 2006
  • Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode..  83:53-63. 2006
  • Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder..  82:261-264. 2006
  • One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia..  81:1-15. 2006
  • Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial..  80:33-43. 2005
  • Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial..  80:1-8. 2005
  • Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III..  80:19-32. 2005
  • The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome..  80:9-18. 2005
  • Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode..  78:161-169. 2005
  • A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.  80:45-53. 2005
  • Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3].  76:127-129. 2005
  • Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia..  72:249-258. 2005
  • The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery..  68:283-297. 2004
  • Abnormalities in MRI-measured signal intensity in the corpus callosum in schizophrenia..  67:277-282. 2004
  • Neuropsychological status of subjects at high risk for a first episode of psychosis..  67:115-122. 2004
  • Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory..  63:201-217. 2003
  • Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia..  60:9-12. 2003
  • Working memory and schizophrenia: evidence for slowed encoding..  59:99-113. 2003
  • Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia..  58:173-183. 2002
  • Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources..  57:51-67. 2002
  • Outcome in children with fetal mild ventriculomegaly: a case series..  48:219-226. 2001
  • IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness..  46:203-207. 2000
  • Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls..  45:169-173. 2000
  • Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia..  41:389-395. 2000
  • Visuospatial working memory in schizotypal personality disorder patients..  41:447-455. 2000
  • Mild ventriculomegaly detected in utero with ultrasound: clinical associations and implications for schizophrenia..  33:133-140. 1998
  • Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?.  29:36-36. 1998
  • Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia..  26:139-146. 1997
  • Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay..  26:9-14. 1997
  • Self-monitoring deficits in schizophrenia: Autonoetic agnosia.  24:110-110. 1997
  • D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder..  20:29-32. 1996
  • Fetal brain development of twins assessed in utero by ultrasound: implications for schizophrenia..  19:141-149. 1996
  • A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia..  17:25-33. 1995
  • Cognitive impairment as a target for pharmacological treatment in schizophrenia..  17:123-129. 1995
  • The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction.  15:123-123. 1995
  • Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function..  11:217-224. 1994
  • CLOZAPINE DECREASES DRIVE TO SMOKE.  11:104-104. 1994
  • Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia..  8:211-221. 1993
  • Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients.  6:136-136. 1992
  • Frontal functioning and plasma HVA in the relatives of schizophrenic patients.  6:158-158. 1992
  • Twin studies of psychopathology: why do the concordance rates vary?.  5:211-221. 1991
  • Kraepelinian schizophrenia: A replication in an independent sample.  4:257-257. 1991
  • Plasma HVA correlates of attentional performance in unmedicated schizophrenics.  4:345-346. 1991
  • Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms..  4:71-79. 1991
  • DORSOLATERAL PREFRONTAL CORTEX DRIVES MESOLIMBIC DOPAMINERGIC REGIONS DURING MOTIVATED BEHAVIOR: INSIGHTS FROM DYNAMIC CAUSAL MODELING AND FMRI IN AT-RISK ADOLESCENTS 2014
  • DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA 2012
  • LONGITUDINAL SUBSTANCE USE TRAJECTORIES FOR PERSONS WITH SCHIZOPHRENIA 2012
  • Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION 2012
  • Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR? 2012
  • COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS) 2010
  • GABA AND GLUTAMATE-GLUTAMINE LEVELS IN THE FRONTAL CORTEX IN SCHIZOPHRENIA: A MAGNETIC RESONANCE SPECTROSCOPY STUDY 2010
  • STATIC AND DYNAMIC COGNITIVE DEFICITS IN CHILDHOOD PRECEDE ADULT SCHIZOPHRENIA: A 30-YEAR STUDY 2010
  • The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison 2006
  • Functional outcomes and characteristics of olanzapine cognitive super-responders 2004
  • Is cognitive improvement with antipsychotic treatment pseudospecific? 2004
  • Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis 2004
  • Poor executive function at age 13 predicts later schizophreniform disorder: A longitudinal birth cohort study 2004
  • The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery 2004
  • The functional hurdle: Connecting through cognition 2004
  • Neurosteroid modulation of GABAergic neurotransmission in the central amygdala 2003
  • Cannabis use in adolescence and risk for adult psychosis: A birth cohort study 2003
  • Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients 2003
  • Schizophrenic-like deficits in nonpsychotic children and adolescents with 22Q11 deletion syndrome 2003
  • Neonatal cerebral ventricle volume: A comparison of 3D ultrasound and MRI 2001
  • Outcome in children with fetal isolated mild ventriculomegaly: A case study 1999
  • Successful treatment of self-monitoring deficits predicts psychotic symptom decrease 1999
  • Laboratory and clinical tests of spatial working memory 1996
  • THE EXTENT OF WORKING-MEMORY DEMANDS PREDICTS RESPONSE TO NEUROLEPTIC MEDICATION ON CONTINUOUS PERFORMANCE TESTS 1994
  • WORKING-MEMORY DEFICITS IN SCHIZOPHRENICS WITH SEVERE SELF-CARE DYSFUNCTION 1994